Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belapectin + Pembrolizumab in Melanoma and HNSCC
NCT04987996Phase 2Withdrawn
- Start
- Jul 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belapectin in melanoma, head and neck squamous cell carcinoma (HNSCC). Planned start Jul 2023; status: withdrawn.
02
Drugs
belapectin
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04987996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987996.